RU2015111523A - ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ - Google Patents
ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ Download PDFInfo
- Publication number
- RU2015111523A RU2015111523A RU2015111523A RU2015111523A RU2015111523A RU 2015111523 A RU2015111523 A RU 2015111523A RU 2015111523 A RU2015111523 A RU 2015111523A RU 2015111523 A RU2015111523 A RU 2015111523A RU 2015111523 A RU2015111523 A RU 2015111523A
- Authority
- RU
- Russia
- Prior art keywords
- hmg
- capsule composition
- pharmaceutical complex
- coa reductase
- composition according
- Prior art date
Links
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title claims abstract 18
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title claims abstract 18
- 229960002198 irbesartan Drugs 0.000 title claims abstract 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract 15
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract 15
- 239000002775 capsule Substances 0.000 title claims abstract 6
- 239000002131 composite material Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000007963 capsule composition Substances 0.000 claims abstract 31
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000000203 mixture Substances 0.000 claims abstract 9
- 239000008187 granular material Substances 0.000 claims abstract 8
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims abstract 7
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims abstract 7
- 239000000654 additive Substances 0.000 claims abstract 7
- 230000000996 additive effect Effects 0.000 claims abstract 7
- 239000003112 inhibitor Substances 0.000 claims abstract 7
- 239000011247 coating layer Substances 0.000 claims abstract 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims abstract 3
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical group CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims abstract 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims abstract 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims abstract 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims abstract 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960005370 atorvastatin Drugs 0.000 claims abstract 2
- 229960001770 atorvastatin calcium Drugs 0.000 claims abstract 2
- 229960005110 cerivastatin Drugs 0.000 claims abstract 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims abstract 2
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims abstract 2
- 229960003765 fluvastatin Drugs 0.000 claims abstract 2
- 229960004844 lovastatin Drugs 0.000 claims abstract 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims abstract 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002797 pitavastatin Drugs 0.000 claims abstract 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims abstract 2
- 229960002965 pravastatin Drugs 0.000 claims abstract 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims abstract 2
- 229960000672 rosuvastatin Drugs 0.000 claims abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims abstract 2
- 229960002855 simvastatin Drugs 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000007902 hard capsule Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 claims 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000007767 bonding agent Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0096036 | 2012-08-31 | ||
| KR1020120096036A KR20140030505A (ko) | 2012-08-31 | 2012-08-31 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| PCT/KR2013/007841 WO2014035190A1 (en) | 2012-08-31 | 2013-08-30 | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015111523A true RU2015111523A (ru) | 2016-10-20 |
Family
ID=50183919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015111523A RU2015111523A (ru) | 2012-08-31 | 2013-08-30 | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20150231085A1 (enExample) |
| EP (1) | EP2890371A4 (enExample) |
| JP (1) | JP2015526509A (enExample) |
| KR (1) | KR20140030505A (enExample) |
| CN (1) | CN104602678A (enExample) |
| AR (1) | AR092385A1 (enExample) |
| AU (1) | AU2013309688A1 (enExample) |
| BR (1) | BR112015004091A2 (enExample) |
| CA (1) | CA2882738A1 (enExample) |
| CL (1) | CL2015000363A1 (enExample) |
| CO (1) | CO7350622A2 (enExample) |
| CR (1) | CR20150124A (enExample) |
| DO (1) | DOP2015000042A (enExample) |
| EA (1) | EA201590474A1 (enExample) |
| EC (1) | ECSP15010617A (enExample) |
| IL (1) | IL237425A0 (enExample) |
| IN (1) | IN2015DN01738A (enExample) |
| MA (1) | MA37953A1 (enExample) |
| MX (1) | MX2015002591A (enExample) |
| NI (1) | NI201500028A (enExample) |
| PE (1) | PE20150402A1 (enExample) |
| PH (1) | PH12015500395A1 (enExample) |
| RU (1) | RU2015111523A (enExample) |
| SG (1) | SG11201500580QA (enExample) |
| TW (1) | TW201414511A (enExample) |
| UY (1) | UY35000A (enExample) |
| WO (1) | WO2014035190A1 (enExample) |
| ZA (1) | ZA201502157B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| BR112019028235B1 (pt) * | 2017-07-25 | 2024-04-30 | Plexxikon, Inc. | Composições e seus métodos de preparação |
| CN110237070A (zh) * | 2019-05-10 | 2019-09-17 | 辽宁大学 | 厄贝沙坦在制备降血脂药物中的应用 |
| EP4247354A4 (en) * | 2020-11-18 | 2025-02-19 | Fb-Hrs, Llc | COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES |
| CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| WO2005118166A2 (en) * | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
| WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| UA99758C2 (ru) * | 2008-03-28 | 2012-09-25 | Феррер Интернасиональ С.А. | Капсула для профилактики сердечно-сосудистых заболеваний |
| KR101230731B1 (ko) * | 2008-04-29 | 2013-02-07 | 한올바이오파마주식회사 | 약제학적 제제 |
| AU2010242938A1 (en) * | 2009-04-30 | 2011-11-17 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| MX2013000824A (es) * | 2010-07-21 | 2013-10-28 | Nucitec Sa De Cv | Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico. |
-
2012
- 2012-08-31 KR KR1020120096036A patent/KR20140030505A/ko not_active Ceased
-
2013
- 2013-08-29 AR ARP130103082A patent/AR092385A1/es unknown
- 2013-08-30 UY UY0001035000A patent/UY35000A/es not_active Application Discontinuation
- 2013-08-30 SG SG11201500580QA patent/SG11201500580QA/en unknown
- 2013-08-30 RU RU2015111523A patent/RU2015111523A/ru not_active Application Discontinuation
- 2013-08-30 EP EP13834178.9A patent/EP2890371A4/en not_active Withdrawn
- 2013-08-30 US US14/420,953 patent/US20150231085A1/en not_active Abandoned
- 2013-08-30 PE PE2015000255A patent/PE20150402A1/es not_active Application Discontinuation
- 2013-08-30 CN CN201380045368.3A patent/CN104602678A/zh active Pending
- 2013-08-30 MX MX2015002591A patent/MX2015002591A/es unknown
- 2013-08-30 IN IN1738DEN2015 patent/IN2015DN01738A/en unknown
- 2013-08-30 BR BR112015004091A patent/BR112015004091A2/pt not_active IP Right Cessation
- 2013-08-30 AU AU2013309688A patent/AU2013309688A1/en not_active Abandoned
- 2013-08-30 EA EA201590474A patent/EA201590474A1/ru unknown
- 2013-08-30 CA CA2882738A patent/CA2882738A1/en not_active Abandoned
- 2013-08-30 TW TW102131242A patent/TW201414511A/zh unknown
- 2013-08-30 WO PCT/KR2013/007841 patent/WO2014035190A1/en not_active Ceased
- 2013-08-30 JP JP2015529684A patent/JP2015526509A/ja active Pending
-
2015
- 2015-02-16 CL CL2015000363A patent/CL2015000363A1/es unknown
- 2015-02-24 PH PH12015500395A patent/PH12015500395A1/en unknown
- 2015-02-25 IL IL237425A patent/IL237425A0/en unknown
- 2015-02-26 DO DO2015000042A patent/DOP2015000042A/es unknown
- 2015-02-27 NI NI201500028A patent/NI201500028A/es unknown
- 2015-03-11 CR CR20150124A patent/CR20150124A/es unknown
- 2015-03-13 CO CO15058341A patent/CO7350622A2/es unknown
- 2015-03-20 EC ECIEPI201510617A patent/ECSP15010617A/es unknown
- 2015-03-27 MA MA37953A patent/MA37953A1/fr unknown
- 2015-03-30 ZA ZA2015/02157A patent/ZA201502157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015500395A1 (en) | 2015-04-27 |
| MA37953A1 (fr) | 2017-01-31 |
| PE20150402A1 (es) | 2015-04-13 |
| CR20150124A (es) | 2015-04-24 |
| WO2014035190A1 (en) | 2014-03-06 |
| ZA201502157B (en) | 2016-10-26 |
| KR20140030505A (ko) | 2014-03-12 |
| DOP2015000042A (es) | 2015-04-30 |
| JP2015526509A (ja) | 2015-09-10 |
| UY35000A (es) | 2014-03-31 |
| SG11201500580QA (en) | 2015-02-27 |
| CN104602678A (zh) | 2015-05-06 |
| EP2890371A4 (en) | 2016-04-06 |
| BR112015004091A2 (pt) | 2017-07-04 |
| CL2015000363A1 (es) | 2015-06-05 |
| AR092385A1 (es) | 2015-04-22 |
| ECSP15010617A (es) | 2015-12-31 |
| MX2015002591A (es) | 2015-06-10 |
| AU2013309688A1 (en) | 2015-02-26 |
| TW201414511A (zh) | 2014-04-16 |
| EA201590474A1 (ru) | 2015-06-30 |
| CO7350622A2 (es) | 2015-08-10 |
| EP2890371A1 (en) | 2015-07-08 |
| IN2015DN01738A (enExample) | 2015-05-29 |
| CA2882738A1 (en) | 2014-03-06 |
| NI201500028A (es) | 2017-01-04 |
| US20150231085A1 (en) | 2015-08-20 |
| IL237425A0 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| JP2005041875A5 (enExample) | ||
| JP2016527006A5 (enExample) | ||
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| RU2007133601A (ru) | УСТОЙЧИВАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ФИКСИРОВАННУЮ ДОЗУ КОМБИНАЦИИ ФЕНОФИБРАТА И ИНГИБИТОРА HMG-CoA-РЕДУКТАЗЫ | |
| MX2010012514A (es) | Niacina y un medicamento nsaid para tratamiento combinado. | |
| WO2013066279A1 (en) | Solid dosage forms comprising ezetimibe | |
| EP2566465A2 (en) | Stable rosuvastatin formulations | |
| CN103282027A (zh) | 包含hmg-coa还原酶抑制剂和阿司匹林的药物复合制剂 | |
| JP6151854B2 (ja) | 心血管疾患の治療用経口製剤 | |
| JP2015526509A (ja) | イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤 | |
| US20120301549A1 (en) | Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor | |
| JP2016520135A5 (enExample) | ||
| CN103957896A (zh) | 包含ω-3脂肪酸和HMG-CoA还原酶抑制剂并具有改善稳定性的口服复合制剂 | |
| RU2016126852A (ru) | Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы | |
| WO2008010008A2 (en) | Cardiovascular combinations using rennin-angiotensin inhibitors | |
| PH12021553276A1 (en) | Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate | |
| WO2012002921A1 (en) | Multiple dosage forms comprising fenofibrate or fenofibric acid in combination with hmg co a reductase inhibitors such as statins | |
| RU2547574C2 (ru) | Лекарственная форма гиполипидемического действия и способ ее изготовления | |
| CA2798707A1 (en) | Association of xanthine oxidase inhibitors and statins and use thereof | |
| RU2014105690A (ru) | Фармацевтическая композиция для перорального введения, содержащая статин | |
| WO2012005709A2 (en) | Pharmaceutical composition comprising valsartan | |
| HK1181685B (en) | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan | |
| RU2010116528A (ru) | Галеновые композиции, содержащие алискирен и валсартан | |
| OA17601A (en) | Oral formulation for the treatment of cardiovascular diseases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180116 |